News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Endosense Completes Enrollment in TOCCASTAR IDE Study of Its TactiCath® Force-Sensing Ablation Catheter



6/13/2012 10:41:40 AM

GENEVA--(BUSINESS WIRE)--Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study. TOCCASTAR is a prospective, randomized, multi-center investigational device exemption (IDE) trial designed to evaluate the safety and effectiveness of the company’s TactiCath force-sensing ablation catheter in patients with symptomatic paroxysmal atrial fibrillation (AF).

Read at BioSpace.com


comments powered by Disqus
Endosense
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES